Highlights
- Empagliflozin significantly improves beta cell glucose sensitivity (bGS) compared to NPH insulin, even when identical glycemic levels are achieved.
- The enhancement of the disposition index suggests that SGLT2 inhibition provides a synergistic benefit to the insulin-secretion-sensitivity axis.
- Mechanistic insights suggest that lower circulating insulin concentrations during SGLT2i therapy may disinhibit beta cells, facilitating improved metabolic responsiveness.
- The study challenges the traditional ‘glucotoxicity-only’ model, proving that the metabolic advantages of SGLT2 inhibitors are partly independent of their glucose-lowering effects.
Background
The progressive decline of pancreatic beta cell function is a hallmark of type 2 diabetes (T2D) pathophysiology. Historically, clinical improvements in beta cell function observed after the initiation of glucose-lowering therapies were attributed primarily to the relief of ‘glucotoxicity’—the deleterious effect of chronic hyperglycemia on insulin secretion and action. While sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently demonstrated the ability to improve metabolic parameters, it has remained unclear whether these benefits are purely secondary to glucose reduction or represent an intrinsic therapeutic advantage over traditional agents like insulin.
As the therapeutic landscape for T2D expands—including the emergence of oral small-molecule GLP-1 receptor agonists and dual/triple incretin mimetics—understanding the specific mechanistic nuances of established classes like SGLT2 inhibitors becomes critical. The study by Thirumathyam et al. (2025) addresses this gap by comparing empagliflozin directly with titrated NPH insulin to determine if SGLT2 inhibition offers unique benefits to beta cell function and insulin sensitivity when the degree of glycemic relief is held constant.
Key Content
Study Design and Methodological Rigor
The research was conducted as an open-label, randomized, cross-over study at Hvidovre Hospital, Denmark. The investigators enrolled 17 individuals with non-insulin-treated type 2 diabetes (BMI ≥ 28 kg/m², duration > 3 months). The cross-over design is particularly robust for metabolic studies as it allows each patient to serve as their own control, minimizing the impact of inter-individual variability in insulin resistance and secretion capacity.
Participants underwent two 5-week treatment periods: one with empagliflozin and one with NPH insulin. Crucially, the insulin dose was titrated specifically to match the glycemic control achieved during the empagliflozin phase (‘equipoised glycemic control’). This allowed researchers to isolate the effects of the drug class from the effects of glucose lowering itself. Sophisticated metabolic testing was utilized, including 5-hour Oral Glucose Tolerance Tests (OGTT), stable isotope tracers to measure endogenous glucose production and tissue disposal, and the calculation of the disposition index—a mathematical representation of beta cell function relative to insulin sensitivity.
Comparative Metabolic Outcomes
The primary finding of the study was that despite reaching the same level of glycemic control, the metabolic profiles of the two treatments differed significantly:
- Beta Cell Glucose Sensitivity (bGS): Empagliflozin treatment resulted in a significantly higher bGS compared to insulin treatment. This indicates that for any given rise in glucose, the beta cells were more ‘alert’ and responsive under SGLT2 inhibition.
- Insulin Sensitivity: Glucose clearance relative to insulin concentrations was higher during the empagliflozin phase. In contrast, NPH insulin treatment required higher circulating insulin levels to achieve the same glucose disposal, reflecting lower overall insulin sensitivity during the exogenous insulin phase.
- Disposition Index: As a composite measure of metabolic health (bGS × insulin sensitivity), the disposition index showed marked improvement with empagliflozin compared to insulin.
The Glucotoxicity Paradox
The study provides a definitive answer to the question of glucotoxicity. Because the insulin-treated group reached the same blood glucose levels as the empagliflozin-treated group, the ‘relief of glucotoxicity’ was equivalent in both arms. Therefore, the superior beta cell function observed in the empagliflozin arm cannot be attributed to lower glucose levels. Instead, the authors propose a ‘disinhibitory effect.’ During insulin therapy, higher systemic insulin concentrations may suppress the endogenous secretory drive of the beta cell. Conversely, by promoting urinary glucose excretion, SGLT2 inhibitors lower the endogenous insulin requirement, potentially ‘resting’ the beta cell or removing the inhibitory feedback of hyperinsulinemia on its own secretion machinery.
Expert Commentary
This study provides high-level evidence that supports a shift in how we view SGLT2 inhibitors. They are not merely ‘glucoretics’ that dump sugar into the urine; they are metabolic modulators that optimize the body’s endogenous endocrine environment. From a clinical perspective, this reinforces the rationale for early SGLT2i initiation. If these drugs can improve beta cell function independently of glucose levels, they may play a more significant role in slowing the progression of T2D than insulin, which, despite its potency in lowering A1c, does not seem to ‘resuscitate’ beta cell sensitivity to the same degree.
However, some limitations must be considered. The sample size of 17, while standard for intensive physiological tracer studies, is small. Additionally, the study utilized NPH insulin—an older basal insulin—rather than ultra-long-acting analogues or prandial insulin, which might influence the comparative insulin sensitivity data. Nevertheless, the use of gold-standard isotopic methods and a cross-over design lends substantial weight to the findings. These results also complement emerging data on other metabolic therapies, such as oral GLP-1 receptor agonists, which are similarly being evaluated for their ability to preserve beta cell mass and function in the long term.
Conclusion
The results from this randomized cross-over trial demonstrate that empagliflozin improves beta cell glucose sensitivity and whole-body insulin sensitivity to a greater extent than titrated insulin therapy. This improvement is independent of the relief of glucotoxicity, suggesting that SGLT2 inhibitors possess unique mechanisms for metabolic restoration—likely related to the reduction of insulin demand and the subsequent disinhibition of beta cell function. These findings emphasize the clinical value of SGLT2 inhibitors as foundational therapy in T2D, not only for glycemic management and cardiorenal protection but also for the preservation of endogenous metabolic capacity.
References
- Thirumathyam R, Richter EA, van Hall G, et al. Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator. Diabetologia. 2025;69(3):764-780. PMID: 41366535.
- Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity. Lancet. 2026;406(10522):2866-2868. PMID: 41421831.